Adipogen/Rapamycin/AG-CN2-0025-C100/100 µg
商品编号：
AG-CN2-0025-C100
品牌：
Adipogen Inc
市场价：
¥500.00
美元价：
300.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Product Details | |
|---|---|
| Synonyms | Sirolimus; Rapamune; NSC 226080; Antibiotic AY-22989; WY-090217; RAPA; SILA 9268A; CCRIS 9024 |
| Product Type | Chemical |
| Properties | |
| Formula | C51H79NO13 |
| MW | 914.2 |
| Merck Index | 14: 8114 |
| CAS | 53123-88-9 |
| RTECS | VE6250000 |
| Source/Host Chemicals | Isolated from Streptomyces hygroscopicus. |
| Purity Chemicals | ≥98% |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO, methanol or chloroform. |
| InChi Key | QFJCIRLUMZQUOT-KIHCOMIKSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
- Antibiotic.
- Antibacterial and antifungal properties [1, 2].
- Forms a complex with FKBP12 and inhibits the mammalian target of rapamycin (mTOR). Inhibits the response to interleukin-2 (IL-2), and thereby blocks activation of T and B cells [3, 5, 6, 11].
- Potent immunosuppressant [4, 10] used as an alternative to calcineurin inhibitors [12].
- Restricts the proliferation of smooth-muscle cells by blocking cell cycle progression at the G1/S transition [7, 13].
- Anti-proliferative. Antitumor compound [14, 15].
- Apoptosis enhancer. Activator of autophagy both in vitro and in vivo [8, 9].
- Anti-HIV and anti-aging compound [16, 17].
- Neuroprotective [18].
- Suppressor for self-renewal and vascular differentiation potential in hemangioma stem cells [19].
- mTORC1 inhibitor [20].
Product References
- Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle: C. Vezina, et al.; J. Antibiot. (Tokyo) 28, 721 (1975)
- Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization: S.N. Sehgal, et al.; J. Antibiot. (Tokyo) 28, 727 (1975)
- Inhibition of T and B lymphocyte proliferation by rapamycin: J.E. Kay, et al.; Immunology 72, 544 (1991)
- FK506 and rapamycin: novel pharmacological probes of the immune response: J.Y. Chang, et al.; TIPS 12, 218 (1991) (Review)
- Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases: J. Chung, et al.; Cell 69, 1227 (1992),
- Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes: W.G. Morice, et al.; J. Biol. Chem. 268, 22737 (1993)
- A mammalian protein targeted by G1-arresting rapamycin-receptor complex: E.J. Brown, et al.; Nature 369, 756 (1994)
- Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells: S. Muthukkumar, et al.; Transplantation 60, 264 (1995)
- Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro: Y. Shi, et al.; Cancer Res. 55, 1982 (1995)
- Mechanism of action of the immunosuppressant rapamycin: F.J. Dumont & Q. Su; Life Sci. 58, 373 (1996) (Review)
- Rapamycin causes poorly reversible inhibition of mTOR and induces p53- independent apoptosis in human rhabdomyosarcoma cells: H. Hosoi, et al.; Cancer Res. 59, 886 (1999)
- Rapamycin in transplantation: a review of the evidence: R.N. Saunders, et al.; Kidney Int. 59, 3 (2001) (Review)
- Rapamycin in cardiovascular medicine: P.N. Ruygrok, et al.; Intern. Med. J. 33, 103 (2003) (Review)
- Rapamycin: an anti-cancer immunosuppressant?: B.K. Law; Crit. Rev. Oncol. Hematol. 56, 47 (2005) (Review)
- Tubers and tumors: rapamycin therapy for benign and malignant tumors: D.R. Plas & G. Thomas; Curr. Opin. Cell Biol. 21, 230 (2009) (Review)
- Potential use of rapamycin in HIV infection: M. Donia, et al.; Br. J. Clin. Pharmacol. 70, 784 (2010) (Review)
- Resveratrol and rapamycin: are they anti-aging drugs? M. Kaeberlein; Bioessays 32, 96 (2010)
- Fighting neurodegeneration with rapamycin: mechanistic insights: J. Bové, et al.; Nat. Rev. Neurosci. 12, 437 (2011) (Review)
- Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma: S. Greenberger, et al.; J. Invest. Dermatol. 131, 2467 (2011)
- Inhibition of the PI3K–Akt and mTORC1 signaling pathways promotes the elongation of vascular endothelial cells: K. Tsuji-Tamura & M. Ogawa; J. Cell Sci. 129, 1165 (2016)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
